Grant: Engage Grants Program
McGill University
$25,000.00
Developing mechanically realistic high-throughput lung tissue culture platforms
EF 2016-17
Résumé
The stiffness of tissues in the body has now been established as a critical parameter in regulating cellularresponse to therapeutic drugs, and this factor has recently been implicated as critically important in the efficacyof drugs identified to target lung disease. However, the stiffness of the matrix surrounding the cell is typicallyignored in conventional high-throughput drug discovery processes, which are conducted on hard, flat plasticdishes. Culturing cells in physiologically-realistic environments is a growing area of research, and may havesignificant commercial value in reducing the cost of the drug discovery pipeline. Traffick Therapeuticsidentifies and develops novel therapeutic molecules for respiratory diseases using a drug discovery pipeline thatcould be made significantly cheaper and more efficient through the use of such high-throughput andphysiologically realistic culture techniques. Although several novel methods are now being developed tomodulate the stiffness of the culture material for high-throughput applications, applying these methods towardsdrug discovery for respiratory diseases is particularly challenging. Cultures of lung cells require an ""air-liquidinterface"" to ensure that cells adopt a physiologically realistic morphology, which cannot be easily integratedwith stiffness-tunable materials, particularly in a high-throughput format. The main goal of this project is toengineer an increased-throughput, mechanically-realistic and air-liquid-interface compatible drug screeningplatform, to determine whether mechanical parameters are important in screening potential therapeuticcompounds. The developed culture systems will be of immediate use to Traffick Therapeutics in prioritizingtheir existing set of target compounds for further development, but may also be broadly applicable torespiratory drug discovery techniques. If successful, this approach will significantly reduce the cost of drugprioritization, enabling Traffick to reduce the cost of their discovery process for novel respiratory targetmolecules.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
501243-2016
Name nom
Moraes, Christopher
Department département
Chemical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1206
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Engineering
Area of application fr
Génie
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Developing mechanically realistic high-throughput lung tissue culture platforms
Keyword
NSERC
Application summary
The stiffness of tissues in the body has now been established as a critical parameter in regulating cellularresponse to therapeutic drugs, and this factor has recently been implicated as critically important in the efficacyof drugs identified to target lung disease. However, the stiffness of the matrix surrounding the cell is typicallyignored in conventional high-throughput drug discovery processes, which are conducted on hard, flat plasticdishes. Culturing cells in physiologically-realistic environments is a growing area of research, and may havesignificant commercial value in reducing the cost of the drug discovery pipeline. Traffick Therapeuticsidentifies and develops novel therapeutic molecules for respiratory diseases using a drug discovery pipeline thatcould be made significantly cheaper and more efficient through the use of such high-throughput andphysiologically realistic culture techniques. Although several novel methods are now being developed tomodulate the stiffness of the culture material for high-throughput applications, applying these methods towardsdrug discovery for respiratory diseases is particularly challenging. Cultures of lung cells require an ""air-liquidinterface"" to ensure that cells adopt a physiologically realistic morphology, which cannot be easily integratedwith stiffness-tunable materials, particularly in a high-throughput format. The main goal of this project is toengineer an increased-throughput, mechanically-realistic and air-liquid-interface compatible drug screeningplatform, to determine whether mechanical parameters are important in screening potential therapeuticcompounds. The developed culture systems will be of immediate use to Traffick Therapeutics in prioritizingtheir existing set of target compounds for further development, but may also be broadly applicable torespiratory drug discovery techniques. If successful, this approach will significantly reduce the cost of drugprioritization, enabling Traffick to reduce the cost of their discovery process for novel respiratory targetmolecules.